ABBV-303 / AbbVie, Dragonfly Therap - LARVOL DELTA

ABBV-303 engages and redirects NK and CD8 T cells to lyse c-Met expressing tumor cells (SITC 2024) - P1 | "Conclusions Overall, our preclinical studies of ABBV-303 demonstrate drug-mediated tumor cell killing and corresponding immune activation supporting clinical testing of this agent. ABBV-303 is currently being tested in a Phase 1 First-in-Human clinical trial in solid tumors as a monotherapy and in combination with an anti-PD-1 checkpoint inhibitor (NCT06158958)."

IO biomarker • Tumor cell • Oncology • Solid Tumor • CD69 • CD8 • FCGR3A • IFNG • MET • NKG2D

ABBV-303: A novel NK and CD8 T cell engager specific for c-Met-expressing tumors (AACR 2024) - "ABBV-303 includes three functional arms: (1) a c-Met binding scFv based on ABT-700, common to c-Met-targeting antibody-drug conjugates ABBV-400 and Teliso-V; (2) a Fab arm that binds NKG2D, a stimulatory receptor expressed by NK cells and activated CD8+ T cells; and (3) a heterodimeric IgG1 Fc which binds CD16a on NK cells and links the other two binding moieties. A benign safety profile was observed in non-human primates through three repeat doses up to 150 mg/kg given every two weeks, with antibody-like exposures and a serum half-life around 8 days. Based on these findings, the First in Human ABBV-303 study will initiate in 1H 2024 in solid tumors as a monotherapy and in combination with an anti-PD-1 checkpoint inhibitor.All authors are current employees of AbbVie."

Oncology • Solid Tumor • CD34 • CD8 • FCGR3A • MET • NKG2D

Dragonfly has Received Milestone Payment Following Dosing of First Patient in AbbVie Phase 1 Clinical Trial Evaluating DF4101/ABBV-303 (PRNewswire) - "Dragonfly Therapeutics, Inc...announced receipt of a milestone payment following dosing of the first patient in a clinical trial conducted by AbbVie...to evaluate ABBV-303, a solid tumor targeting TriNKET....The Phase 1 clinical trial, conducted by AbbVie, is evaluating ABBV-303 alone and in combination with AbbVie's budigalimab (ABBV-181), in solid tumors."

Financing • Trial status • Oncology • Solid Tumor

A Study of Adverse Events, How Intravenously (IV) Infused ABBV-303 Moves Through the Body, and Change in Disease State, as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181), in Adult Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=181 | Recruiting | Sponsor: AbbVie | Not yet recruiting ➔ Recruiting

Enrollment open • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • Squamous Cell Carcinoma of Head and Neck

A Study of Adverse Events, How Intravenously (IV) Infused ABBV-303 Moves Through the Body, and Change in Disease State, as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181), in Adult Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=181 | Not yet recruiting | Sponsor: AbbVie

Adverse events • Combination therapy • Metastases • Monotherapy • New P1 trial • Pan tumor • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • Squamous Cell Carcinoma of Head and Neck